Jump to navigation Jump to search
Clinical data
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass429.43 g/mol

WikiDoc Resources for Dopexamine


Most recent articles on Dopexamine

Most cited articles on Dopexamine

Review articles on Dopexamine

Articles on Dopexamine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Dopexamine

Images of Dopexamine

Photos of Dopexamine

Podcasts & MP3s on Dopexamine

Videos on Dopexamine

Evidence Based Medicine

Cochrane Collaboration on Dopexamine

Bandolier on Dopexamine

TRIP on Dopexamine

Clinical Trials

Ongoing Trials on Dopexamine at Clinical

Trial results on Dopexamine

Clinical Trials on Dopexamine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Dopexamine

NICE Guidance on Dopexamine


FDA on Dopexamine

CDC on Dopexamine


Books on Dopexamine


Dopexamine in the news

Be alerted to news on Dopexamine

News trends on Dopexamine


Blogs on Dopexamine


Definitions of Dopexamine

Patient Resources / Community

Patient resources on Dopexamine

Discussion groups on Dopexamine

Patient Handouts on Dopexamine

Directions to Hospitals Treating Dopexamine

Risk calculators and risk factors for Dopexamine

Healthcare Provider Resources

Symptoms of Dopexamine

Causes & Risk Factors for Dopexamine

Diagnostic studies for Dopexamine

Treatment of Dopexamine

Continuing Medical Education (CME)

CME Programs on Dopexamine


Dopexamine en Espanol

Dopexamine en Francais


Dopexamine in the Marketplace

Patents on Dopexamine

Experimental / Informatics

List of terms related to Dopexamine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Dopexamine is a synthetic analogue of dopamine. Despite this, it is a β1 and β2-adrenergic receptor agonist.[1] Its action at dopamine receptor D1 mediates relaxation of vascular smooth muscle in renal, mesenteric, cerebral and coronary arteries. Mild action at D2 receptors decreases noradrenaline release.[2]

Use in sepsis has been proposed.[3]

It is used as an inotropic agent in cardiac failure.[4] Side effects include arrhythmia, tremor, angina and flushing.


  1. Perrin G, Papazian L, Martin C. (1993). "Dopexamine: a new dopaminergic agonist". Ann Fr Anesth Reanim. 12 (3): 308–320. PMID 7902685.
  2. Brown RA, Dixon J, Farmer JB; et al. (July 1985). "Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors". Br. J. Pharmacol. 85 (3): 599–608. doi:10.1111/j.1476-5381.1985.tb10554.x. PMC 1916510. PMID 2862944.
  3. Birnbaum J, Klotz E, Spies CD; et al. (2006). "Effects of dopexamine on the intestinal microvascular blood flow and leucocyte activation in a sepsis model in rats". Crit Care. 10 (4): R117. doi:10.1186/cc5011. PMC 1750974. PMID 16893450.
  4. Lisbon A (May 2003). "Dopexamine, dobutamine, and dopamine increase splanchnic blood flow: what is the evidence?". Chest. 123 (5 Suppl): 460S–3S. doi:10.1378/chest.123.5_suppl.460S. PMID 12740229.

Template:Cardiac stimulants excluding cardiac glycosides